| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3281779 | Clinical Gastroenterology and Hepatology | 2014 | 8 Pages |
Abstract
In a well-characterized cohort of patients with HCV, a large proportion (40%) with IL28B polymorphisms associated with response to therapy is ineligible for treatment because of contraindications. One potential role of IL28B genotype analysis could be to identify patients who, although not currently eligible for antiviral treatment, could become so by modifying fixable exclusions to treatment.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Fasiha Kanwal, Donna L. White, Shahriar Tavakoli-Tabasi, Li Jiao, Derek Lin, David J. Ramsey, Andrew Spiegelman, Jill Kuzniarek, Hashem B. El-Serag,